PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASES: MODERN VIEWS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Primary sclerosing cholangitis (PSC) is a chronic autoimmune cholestatic liver disease characterized by a progressive course leading to the development of liver cirrhosis. The feature of this disease includes a close relationship with inflammatory bowel diseases (ulcerative colitis and Crohn’s disease). PSC and inflammatory bowel diseases are complex pathological conditions; their etiopathogenesis is associated with a genetic predisposition, immune mechanisms, altered intestinal microbiota, and probably having a common mechanisms, and is not fully understood. For the combination of PSC and inflammatory bowel diseases, a certain phenotype is characteristic, differing in the isolated course of these nosologies. This research was carried out to review current scientific data on epidemiology, demography, etiopathogenetic mechanisms, clinical features, mutual influence of associated diseases, diagnosis and treatment of patients with PSC combined with inflammatory bowel diseases.

Full Text

Restricted Access

About the authors

E. V Skazyvaeva

NWSMU n.a. I.I. Mechnikov

Email: skazyvaeva@yandex.ru
PhD, Associate Professor, Associate Professor at the Department of Propaedeutics of Interna! Diseases, Gastroenterology and Dietology

I. G Bakulin

NWSMU n.a. I.I. Mechnikov

Department of Propaedeutics of Internal Diseases, Gastroenterology and Dietology

E. B Avaluyeva

NWSMU n.a. I.I. Mechnikov

Department of Propaedeutics of Internal Diseases, Gastroenterology and Dietology

M. I Skalinskaya

NWSMU n.a. I.I. Mechnikov

Department of Propaedeutics of Internal Diseases, Gastroenterology and Dietology

References

  1. Hirschfield G.M., Karlsen T.H., Lindor K.D., et al. Primary sclerosing cholangitis. Lancet. 2013;382:1587-99. Doi: 10. 1016/S0140-6736(13)60096-3.
  2. Boonstra K., van Erpecum K.J., van Nieuwkerk K.M., et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2270-76. doi: 10.1002/ibd.22938.
  3. Boberg K.M., Aadland E., Jahnsen J., et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33:99-103. doi: 10.1080/00365529850166284.
  4. Moiodecky N.A., Kareemi H., Parab R., et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53:1590-99. doi: 10.1002/hep.24247.
  5. Chapman R., Fevery J., Kalloo A., et ai. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660-78. Doi: 10.1002/ hep.23294.
  6. Rossi R.E., Conte D., Massironi S. Primary sclerosing cholangitis associated with inflammatory bowel disease: an update. Eur J Gastroenterol Hepatol. 2016;28:123-31. doi: 10.5009/gnl16510.
  7. de Vries A.B., Janse M., Blokziji H. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol. 2015:21.1956-71. doi: 10.3748/wjg.v21. 6.1956.
  8. Tanaka A., Takamori Y, Toda G., et al. Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int. 2008;28:983-89. doi: 10.1111/j.1478- 3231.2008.01726.x.
  9. Shorbagi A., Bayraktar Y Primary sclerosing cholangitis: what is the difference between east and west? World J Gastroenterol. 2008;14:3974-81. doi: 10.3748/wjg.14.3974.
  10. Sano H., Nakazawa T, Ando T., et al. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2011;18.154-61. doi: 10.1007/S00534-010-0319-8.
  11. Schaeffer D.F., Win L.L., Hafezi-Bakhtiari S., et al. The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis. Dig DisSci. 2013;58:2608-14.
  12. Nakazawa T, Naitoh I., Hayashi K., et al. Inflammatory bowel disease of primary sclerosing cholangitis: a distinct entity? World J Gastroenterol. 2014;20:3245-54. doi: 10.3748/wjg.v20. i12.3245.
  13. Jorgensen K.K., Grzyb K., Lundin K.E., et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis. 2012;18:536-45.
  14. Loftus E.V., Jr, Harewood G.C., Loftus C.G., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91-96. Doi: 10.1136/ gut.2004.046615.
  15. Joo M., Abreu-e-Lima P., Farraye F., et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol. 2009;33: 854-62. Doi: 10.1097/ PAS.0b013e318196d018.
  16. Sinakos E., Samuel S., Enders F., et al. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis. 2013;19:1004-1009. Doi: 10.1097/ MIB.0b013e3182802893.
  17. Rojas-Feria M., Castro M., Suarez E., Ampuero J., et al. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol. 2013;19:7327-40. doi: 10.3748/wjg.v19.i42.7327.
  18. Jostins L., Ripke S., Weersma R.K., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-24. Doi: 10.1038/ nature11582.
  19. Huang C., Haritunians T., Okou D.T. et al. Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans. Gastroenterology. 2015;149:1575-86. Doi: 10.1053/j. gastro.2015.07.065.
  20. Henriksen E.K., Melum E., Karlsen T.H. Update on primary sclerosing cholangitis genetics. Curr Opin Gastroenterol 2014;30:310-19. Doi: 10.1097/ M0G.0000000000000052.
  21. Liu J.Z., Hov J.R., Folseraas T., et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet. 2013;45:670-75. doi: 10.1038/ng.2616.
  22. Tsaitas C., Semertzidou A., Sinakos E. Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol. 2014;6:178-87. Doi: 10.4254/ wjh.v6.i4.178.
  23. Grant A.J., Lalor P.F., Salmi M., et al. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002;359:150-57. doi: 10.1016/S0140-6736(02)07374-9.
  24. Eksteen B., Grant A.J., Miles A., et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med. 2004;200:1511-17. Doi: 10.1084/ jem.20041035.
  25. Cesaro C., Tiso A., Del Prete A., et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis. 2011;43:431-38. Doi: 10.1016/j. dld.2010.10.015.
  26. Tabibian J.H., Varghese C., LaRusso N.F. The enteric microbiome in hepatobiliary health and disease. Liver Int. 2016;36:480-87. Doi: 10.1111/ liv.13009.
  27. Torres J., Pineton de Chambrun G., Itzkowitz S., et al. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther, 2011;34:497-508. doi: 10.1111/j.1365-2036.2011.04753.x.
  28. Duboc H., Rajca S., Rainteau D., et al. Connecting dysbiosis, bileacid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013;62:531-39. Doi: 10.1136/ gutjnl-2012-302578.
  29. Quraishi M.N., Sergeant M., Kay G., et al. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. Gut. 2017;66:386-88. Doi: 10.1136/ gutjnl-2016-311915.
  30. Kummen M., Holm K., Anmarkrud J.A., et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut. 2017;66:611-19. Doi: 10.1136/ gutjnl-2015-310500.
  31. Tabibian J.H., O'Hara S.P., Trussoni C.E., et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology. 2016;63:185-96. doi: 10.1002/hep.27927.
  32. Torres J., Palmela C., Brito H., et al. The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. United Eur Gastroenterol J. 2018;6(1):112-22. doi: 10.1177/2050640617708953.
  33. Keith D. Lindor M.D., Kris V., et al. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol, 2015;110:646-59.
  34. Chapman R., Fevery J., Kalloo A., et al. AASLD Practice Guidelines: Diagnosis and Management of Primary Sclerosing Cholangitis. J Hepatology. 2010;51(2):660-78.
  35. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatology. 2009;51(2):237-67. Doi:10.1016/j. jhep.2009.04.009.
  36. Harbord M., Annese V, Vavricka S.R., et al. The first European evidence-based consensus on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10:239-54. doi: 10.1093/ecco-jcc/jjv213.
  37. European Society of Gastrointestinal Endoscopy, European Association for the Study of the Liver. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. J Hepatol. 2017;66(6):1265-81.
  38. Bakulin I., Shalikiani N., Kharlamenkov E. Difficult to diagnose case of primary sclerosing cholangitis in young woman (статья) ournal of Liver and Clinical Research. November, 015. URL: http:// www.jscimedcentral.com/Liver/liver-2-1019.
  39. Halliday J.S., Djordjevic J., Lust M. et al. A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease. J Crohns Colitis. 2012;6:174-81. Doi: 10.1016/j. crohns.2011.07.015.
  40. Yanai H., Matalon S., Rosenblatt A., et al. Prognosis of primary sclerosing cholangitis in Israel is independent of coexisting inflammatory bowel Disease. J Crohns Colitis. 2015;9:177-84. doi: 10.1093/ecco-jcc/jju013.
  41. Navaneethan U., Venkatesh PG., Lashner B.A. et al. The impact of ulcerative colitis on the long-term outcome of patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2012;35:1045-53. doi: 10.1111/j.1365-2036.2012.05063.x.
  42. Marelli L., Xirouchakis E., Kalambokis G., et al. The severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut. 2011;60:1224-28. Doi: 10.1136/ gut.2010.235408.
  43. Jess T., Simonsen J., Jergensen K.T, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143:375-81. Doi: 10.1053/ j.gastro.2012.04.016.
  44. Imam M.H., Thackeray E.W., Lindor K.D. Colonic neoplasia in young patients with inflammatory bowel disease and primary sclerosing cholangitis. Colorectal Dis. 2013;15:198-203. doi: 10.1111/j.1463-1318.2012.03133.x.
  45. Marchesa P,.Lashner B.A., Lavery I.C., et ai. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1997;92:1285-88.
  46. Lindberg B.U., Broomé U., Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum. 2001;44:77-5.
  47. Sokol H., Cosnes J., Chazouilleres O., et al. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol. 2008;14:3497-03.
  48. Navaneethan U., Choudhary M., Venkatesh P.G., et al. The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2012;35:1054-63. doi: 10.1111/j.1365-2036.2012.05067.x.
  49. Mosli M., Croome K., Qumosani K., et al. The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease. Gastroenterol Hepatol (N.Y). 2013;9:434-41.
  50. Moncrief K.J., Savu A., Ma M.M., et al. The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation: a single-centre experience. Can J Gastroenterol. 2010;24:4046. doi: 10.1155/2010/830291.
  51. Verdonk R.C., Dijkstra G., Haagsma E.B., et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant. 2006;6:1422-29. doi: 10.1111/j.1600-6143.2006.01333.x.
  52. Marelli L., Xirouchakis E., Kalambokis G., et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut. 2011;60: 1224-28. Doi: 10.1136/ gut.2010.235408.
  53. Jorgensen K.K., Grzyb K., Lundin K.E., et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis. 2012;18:536-45. doi: 10.1002/ibd.21699.
  54. Singh S., Loftus E.V., Jr, Talwalkar J.A. Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol. 2013;108:1417-25. Doi: 10.1038/ ajg.2013.163.
  55. Cholongitas E., Shusang V, Papatheodoridis G.V, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008;14:138-43. Doi: 10.1002/ lt.21260.
  56. Ивашкин В.Т., Широкова Е.Н., Маевская М.В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению холестаза. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;2:41-57.
  57. Olsson R., Boberg K.M., de Muckadell O.S., et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129:1464-72.
  58. Hansen J.D., Kumar S., Lo WK., et al. Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis. Dig Dis Sci. 2013;58(11):30 79-87.
  59. Cheung A.C., Lazaridis K.N., LaRusso N.F., Gores G.J. Emerging pharmacologic therapies for primary sclerosing cholangitis. Curr Opin Gastroenterol. 2017;33(3):149-57. Doi: 10.1097/ MOG.0000000000000352.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies